Lutz Lingnau is Director at NEKTAR THERAPEUTICS (NKTR). They have made 11 open-market trades across 1 company since 2014, most recently 2020-09-22.
CIK 0001354179
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NKTR | 35,800 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2020-09-25 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKTR | SELL | 2019-09-27 | 2019-10-02 | $17.84 | $54K | -7.9% | +6.3% | +25.3% |
| NKTR | SELL | 2019-07-08 | 2019-07-10 | $34.63 | $346K | -7.5% | -40.2% | -53.7% |
| NKTR | SELL | 2018-09-20 | 2018-09-21 | $56.98 | $513K | -7.9% | -31.7% | -44.1% |
| NKTR | SELL | 2018-04-05 | 2018-04-09 | $101.74 | $3.1M | -14.6% | -26.3% | -55.0% |
| NKTR | SELL | 2017-09-22 | 2017-09-25 | $21.97 | $110K | +8.0% | +5.7% | +162.4% |
| NKTR | SELL | 2017-07-14 | 2017-07-18 | $20.76 | $623K | +4.9% | -15.7% | +8.3% |
| NKTR | SELL | 2017-04-07 | 2017-04-11 | $20.05 | $140K | +2.5% | +5.5% | +6.0% |
| NKTR | SELL | 2017-02-21 | 2017-02-23 | $13.08 | $392K | +8.9% | +78.6% | +61.2% |
| NKTR | SELL | 2016-09-15 | 2016-09-19 | $19.06 | $172K | -11.9% | -30.6% | -32.6% |
| NKTR | SELL | 2016-04-25 | 2016-04-27 | $16.27 | $244K | -16.1% | -6.2% | -6.4% |
| NKTR | SELL | 2016-01-20 | 2016-01-21 | $14.51 | $218K | -17.1% | -21.6% | +4.8% |
| NKTR | SELL · 10b5-1 | 2015-10-28 | 2015-10-30 | $12.00 | $150K | -19.7% | -1.3% | -16.5% |
| NKTR | SELL · 10b5-1 | 2015-06-15 | 2015-06-17 | $11.15 | $279K | -19.7% | -1.3% | -1.3% |
| NKTR | SELL · 10b5-1 | 2014-11-24 | 2014-11-26 | $15.02 | $225K | -19.7% | -1.3% | -1.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.